Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed
Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines.
대표청구항▼
1. A composition comprising a pharmaceutically acceptable carrier, an adjuvant, and a mixture of at least one major histocompatibility complex (MHC) class I peptide epitope of 8-10 amino acids in length derived from a mesothelin antigen variant having an amino acid sequence selected from the group c
1. A composition comprising a pharmaceutically acceptable carrier, an adjuvant, and a mixture of at least one major histocompatibility complex (MHC) class I peptide epitope of 8-10 amino acids in length derived from a mesothelin antigen variant having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 19-25 and at least one MHC class I peptide epitope of 8-10 amino acids in length derived from each of at least six different antigens or variants thereof selected from the group consisting of: a mesothelin antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-18;an NY-ESO-1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 26 and SEQ ID NO: 27;an FBP antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO: 28 and SEQ ID NO: 29;a HER-2/neu antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 30-48;an IL-13 receptor α2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence of SEQ ID NO: 49;a MAGE-A1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-55;an EphA2 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-68;a p53 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:69-80;a k-Ras antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:81-86;an Ep-CAM antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:87-91;a MUC1 antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NO:92 and SEQ ID NO:93;a survivin antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:94-98;an hTERT antigen or variant thereof, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs:99-104; anda WT1 antigen, wherein the MHC class I peptide epitope has an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-109. 2. The composition of claim 1, wherein the composition comprises at least one MHC class I peptide epitope of 8-10 amino acids in length derived from a mesothelin antigen, an NY-ESO-1 antigen, an FBP antigen, a HER-2/neu antigen, an IL-13 receptor α2 antigen, a MAGE-A1 antigen, and an EphA2 antigen. 3. The composition of claim 1, wherein said composition comprises: the MHC class I peptide epitope derived from an NY-ESO-1 antigen having the amino acid sequence of SEQ ID NO: 26;the MHC class I peptide epitope derived from an FBP antigen having the amino acid sequence of SEQ ID NO: 28;the MHC class I peptide epitope derived from a HER-2/neu antigen having the amino acid sequence of SEQ ID NO: 40;the MHC class I peptide epitope derived from a IL-13 receptor α2 antigen having the amino acid sequence of SEQ ID NO: 49;the MHC class I peptide epitope derived from a MAGE-A1 antigen having the amino acid sequence of SEQ ID NO: 55; andthe MHC class I peptide epitope derived from an EphA2 antigen having the amino acid sequence of SEQ ID NO: 66. 4. The composition of claim 1, wherein the composition further comprises any one or more of dextrose, dimethyl sulphoxide (DMSO), and dextran. 5. The composition of claim 1, wherein each of the MHC class I peptide epitopes is present in the composition at a concentration between about 10 μg/ml and about 20 μg/ml. 6. The composition of claim 1, wherein each of the MHC class I peptide epitopes is present in the composition at a concentration of 20 μg/ml. 7. The composition of claim 1, wherein each of the MHC class I peptide epitopes is present in the composition at a concentration of 2 μg/ml. 8. The composition of claim 1, wherein each of the MHC class I peptide epitopes is pegylated.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (52)
Rosenberg Steven A. (Bethesda MD), Adoptive immunotherapy as a treatment modality in humans.
Graus, Yvo Maria Franciscus; Smit, Hobbe Friso; Osterhaus, Albertus Dominicus Marcellinus Erasmus; Hageman, Robert Johan Joseph, Chlorogenic acid and an analog thereof for immune system stimulation.
Altman John D. (San Carlos CA) McHeyzer-Williams Michael G. (Menlo Park CA) Davis Mark M. (Atherton CA), Compositions and methods for the detection, quantitation and purification of antigen-specific T cells.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is a.
Hideaki Tahara JP; Michael T. Lotze ; Yasuhiko Nishioka JP, In situ injection of antigen-presenting cells with genetically enhanced cytokine expression.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Cohen Peter A. ; Czerniecki Brian J. ; Koski Gary K. ; Weng David E. ; Carter Charles ; Ojeifo John O. ; Schwartz Gretchen N., Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells.
Cohen Peter A. (Bethesda MD) Czerniecki Brian J. (Gaithersburg MD) Carter Charles (Gaithersburg MD) Fowler Daniel H. (Bethesda MD) Kim Hyun (Rochester MN), Method for isolating dendritic cells.
Edward L. Nelson ; Susan L Strobl, Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells.
Storkus Walter J. ; Lotze Michael T., Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients.
Boon Thierry,BEX ; Van Der Bruggen Pierre,BEX ; Van Den Eynde Benoit,BEX ; Van Pel Aline,BEX ; De Plaen Etienne,BEX ; Lurquin Christophe,BEX ; Chomez Patrick,BEX ; Traversari Catia,ITX, Tumor rejection antigen precursors, tumor rejection antigens and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.